FDA Issues Class I Recall for One Source Nutrition's Vitality Product Amid Undeclared Sildenafil and Tadalafil Contamination
One Source Nutrition, Inc. faces a Class I FDA recall (D-0281-2025) for its "Vitality" male enhancement product, tainted with undeclared sildenafil and tadalafil. This nationwide U.S. recall underscores critical regulatory and quality control failures, posing significant risks to consumer health and demanding immediate action from supply chain partners to assess product integrity and ensure compliance with drug approval standards.
FDA Initiates Class I Recall for One Source Nutrition's Tainted Male Enhancement Product
The U.S. Food and Drug Administration (FDA) has initiated a Class I recall, D-0281-2025, for "Vitality, Fast Acting Male Enhancement Product, Dietary Supplement," manufactured by One Source Nutrition, Inc. This critical action, voluntarily initiated by the firm on February 20, 2025, stems from the product being marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Crucially, the product was found to be tainted with undeclared sildenafil and tadalafil, active pharmaceutical ingredients (APIs) typically found in prescription medications for erectile dysfunction. This poses a severe risk to consumers, particularly those with underlying health conditions or taking nitrate-containing drugs, as the interaction can lead to dangerously low blood pressure. For procurement directors and regulatory affairs heads, this event highlights the imperative for stringent quality control and regulatory oversight within the dietary supplement sector. The presence of undeclared APIs in a product marketed as a dietary supplement constitutes adulteration and misbranding, demanding immediate attention to supply chain integrity and product formulation verification. The recall covers all lots of the product, distributed nationwide in the U.S.A., impacting both individual capsules (300 units) and six-capsule bottles (20 units) of the "Xtreme Potency" variant.
Operational Footprint and Distribution Network of One Source Nutrition
One Source Nutrition, Inc., based at 19863 Interstate 30 S, Benton, AR 72015-6966, United States, is the entity responsible for the recalled "Vitality" product. The firm's distribution pattern is described as nationwide across the U.S.A., indicating a broad market reach for the tainted product. The initial notification from the firm regarding the recall was conducted via e-mail, signaling their voluntary initiation of this corrective action. For supply chain VPs and business development executives, this geographic scope means that any entity involved in the distribution, retail, or online sales of this product across the United States is directly impacted and must ensure immediate cessation of sales and retrieval of all affected inventory. The relatively small reported quantities – 300 individually wrapped capsules and 20 bottles – might suggest a smaller-scale operation, but the Class I classification underscores the severity of the health risk, irrespective of volume. The lack of specific facility details beyond the primary address in Benton, Arkansas, limits the ability to assess the full manufacturing footprint or potential for other affected products. However, the nationwide distribution necessitates a comprehensive and rapid response from all downstream partners to mitigate consumer exposure and regulatory liabilities.
Critical Supply Chain Implications: Mitigating Risk from Undeclared APIs
The discovery of undeclared sildenafil and tadalafil in a dietary supplement carries profound implications for supply chain integrity and regulatory compliance. Sildenafil, the active ingredient in Viagra, and tadalafil, in Cialis, are potent phosphodiesterase-5 (PDE5) inhibitors that require medical supervision due to significant side effects and drug interactions, particularly with nitrates, which can cause life-threatening drops in blood pressure. For procurement directors, this incident with One Source Nutrition, Inc. underscores the critical need for robust vendor qualification processes, extending beyond basic quality checks to include comprehensive analytical testing for potential adulterants, especially in the high-risk male enhancement supplement category. Regulatory affairs heads must ensure that product formulations are rigorously vetted against approved drug lists and that all marketing claims align strictly with regulatory classifications. Any product making drug-like claims or containing drug ingredients without an approved NDA/ANDA is subject to severe enforcement. This event serves as a stark reminder that the 'dietary supplement' label does not exempt products from containing undeclared, potent pharmaceutical ingredients, creating significant health hazards and legal exposure for all entities in the distribution chain.
Regulatory Compliance Landscape and Market Alternatives
The current intelligence does not indicate any prior FDA Warning Letters, 483s, or Import Alerts specifically associated with One Source Nutrition, Inc. This suggests that the current Class I recall, D-0281-2025, represents the primary public regulatory action against the company within our available data. For regulatory affairs and business development executives, this lack of a documented history does not diminish the severity of the current violation but highlights the importance of continuous monitoring, as a single significant breach can rapidly escalate. Furthermore, our knowledge graph does not identify specific alternative suppliers for the "Vitality" product or similar male enhancement dietary supplements from One Source Nutrition, Inc. This absence underscores a broader challenge for procurement teams: identifying and qualifying alternative, compliant sources in a market segment often plagued by adulteration. Companies relying on such products for their portfolio must conduct extensive due diligence on all potential suppliers, focusing on their quality management systems, analytical testing capabilities, and regulatory compliance track record, irrespective of their public enforcement history. The FDA's consistent vigilance over this product category means that all market participants must maintain heightened scrutiny.
Forward Outlook: Remediation Requirements and Market Repercussions
As the recall D-0281-2025 by One Source Nutrition, Inc. remains "Ongoing," the firm is obligated to undertake comprehensive corrective actions. This includes thoroughly investigating the root cause of the undeclared sildenafil and tadalafil contamination and the unapproved drug marketing, implementing robust corrective and preventive actions (CAPA), and ensuring the complete removal of all affected products from the market. The FDA will closely monitor the effectiveness of the recall and may conduct follow-up inspections at One Source Nutrition's Benton, AR facility to verify compliance. For supply chain VPs, the ongoing status means continued vigilance is required; distributors and retailers must ensure their inventory is purged and returns are processed according to FDA guidelines. Failure to comply with recall procedures can result in further FDA enforcement, including potential Warning Letters, injunctions, or even criminal penalties. Beyond regulatory sanctions, the reputational damage from a Class I recall, particularly involving undeclared APIs, can be severe and long-lasting, impacting future market access and consumer trust. This event serves as a critical reminder for all industry stakeholders to prioritize product safety and regulatory adherence to safeguard public health and maintain market credibility.